Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMWLIPJ)

Drug Name
MAXY-G34 Drug Info
Synonyms Maxy-G21; MAXY-G-CSF; G-CSF agonist (neutropenia, leukopenia), Maxygen
Indication
Disease Entry ICD 11 Status REF
Neutropenia 4B00.0 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMWLIPJ

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Granulocyte colony-stimulating factor receptor (G-CSF-R) TTC70AJ CSF3R_HUMAN Agonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Granulocyte colony-stimulating factor receptor (G-CSF-R) DTT CSF3R 4.087 3.406 3.17 3.322
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Neutropenia
ICD Disease Classification 4B00.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Granulocyte colony-stimulating factor receptor (G-CSF-R) DTT CSF3R 2.08E-08 0.36 0.96
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00501332) Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy. U.S. National Institutes of Health.
2 Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors. Health Phys. 2014 Jan;106(1):21-38.